{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:46:42Z","timestamp":1790520402216,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jaad.2017.12.024","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T18:31:35Z","timestamp":1513276295000},"page":"S76-S83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"S1","title":["New therapies for atopic dermatitis: Additional treatment classes"],"prefix":"10.1016","volume":"78","author":[{"given":"Paras P.","family":"Vakharia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2017.12.024_bib1","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC phase three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2017.12.024_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.clindermatol.2014.12.004","article-title":"Epidemiology of childhood atopic dermatitis","volume":"33","author":"Garg","year":"2015","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/jid.2014.325","article-title":"Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study","volume":"135","author":"Silverberg","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.12.024_bib4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2017.12.024_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/all.12049","article-title":"Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine","volume":"67","author":"Bieber","year":"2012","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jaad.2017.12.024_bib6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014part II: immune cell subsets and therapeutic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2017.12.024_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clindermatol.2011.08.019","article-title":"Abnormal epidermal barrier in the pathogenesis of contact dermatitis","volume":"30","author":"Proksch","year":"2012","journal-title":"Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.12.024_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI21060","article-title":"New insights into atopic dermatitis","volume":"113","author":"Leung","year":"2004","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jaad.2017.12.024_bib9","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/nbt1267","article-title":"Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies","volume":"24","author":"Hancock","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"13","key":"10.1016\/j.jaad.2017.12.024_bib10","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00018-011-0710-x","article-title":"Multifunctional cationic host defence peptides and their clinical applications","volume":"68","author":"Yeung","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10.1016\/j.jaad.2017.12.024_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.sder.2008.04.002","article-title":"Antimicrobial peptides, skin infections, and atopic dermatitis","volume":"27","author":"Hata","year":"2008","journal-title":"Semin Cutan Med Surg"},{"issue":"15","key":"10.1016\/j.jaad.2017.12.024_bib12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"New Eng J Med"},{"issue":"5","key":"10.1016\/j.jaad.2017.12.024_bib13","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.jid.2017.02.238","article-title":"Atopic dermatitis is associated with increased risk of serious infections in US children and adults","volume":"137","author":"Narla","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.12.024_bib20","unstructured":"Friedland HD, Sharp DD, Erfle DJ, et\u00a0al. Omiganan (MBI 226) 1% gel: a novel topical antimicrobial agent with a favorable safety profile. Abstract presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 14-17, 2003; Chicago, Il."},{"issue":"10","key":"10.1016\/j.jaad.2017.12.024_bib21","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"7515","key":"10.1016\/j.jaad.2017.12.024_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature13684","article-title":"AhR sensing of bacterial pigments regulates antibacterial defence","volume":"512","author":"Moura-Alves","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jaad.2017.12.024_bib23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2014.04.019","article-title":"Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions","volume":"40","author":"Di Meglio","year":"2014","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jaad.2017.12.024_bib24","first-page":"917","article-title":"Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis","volume":"123","author":"van den Bogaard","year":"2013","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.jaad.2017.12.024_bib25","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jid.2017.07.815","article-title":"Resolving inflammation by targeting an ancient innate immune sensor with a bacterial metabolite","volume":"137","author":"Johnston","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.12.024_bib27","unstructured":"Peppers J, Maeda-Chubachi T, Wu S, Robbins K, Kraus J. Dose-finding study of GSK2894512 cream for treatment of plaque psoriasis, late-breaking research forum clinical trials. Presented at (F1056): American Academy of Dermatology Annual Meeting; March 2017; Orlando, Fl."},{"issue":"4","key":"10.1016\/j.jaad.2017.12.024_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/archdermatol.2010.34","article-title":"Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial","volume":"146","author":"Bissonnette","year":"2010","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.12.024_bib29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial","volume":"166","author":"Bissonnette","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.12.024_bib31","unstructured":"Peppers J, Maeda-Chubachi T, Wu S, et\u00a0al. A dose-finding study of tapinarof (GSK2894512) cream for the treatment of atopic dermatitis. Poster presented (P0256) at: the European Academy of Dermatology and Venereology Annual Meeting 2017 (EADV 2017); September 13, 2017; Geneva, Switzerland."},{"issue":"6","key":"10.1016\/j.jaad.2017.12.024_bib32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.anai.2017.08.289","article-title":"Efficacy of bleach baths in reducing severity of atopic dermatitis: a systematic review and meta-analysis","volume":"119","author":"Chopra","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2017.12.024_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s13671-013-0052-z","article-title":"Topical hypochlorous acid (HOCl) as a potential treatment of pruritus","volume":"2","author":"Pelgrift","year":"2013","journal-title":"Curr Derm Rep"},{"key":"10.1016\/j.jaad.2017.12.024_bib34","unstructured":"Friedman AJ, Cash K, Berman B. Hypochlorous acid is antiinflammatory and immunomodulatory. Poster presented at: the Winter Clinical Dermatology Conference; January 18, 2013; Kauai, HI."},{"key":"10.1016\/j.jaad.2017.12.024_bib35","unstructured":"Sampson M. Hypochlorous acid demonstrates potent anti-inflammatory activity in\u00a0vitro. Poster presented at: the Dermatology Innovation Forum; March 12, 2013; Orlando, FL."},{"issue":"12","key":"10.1016\/j.jaad.2017.12.024_bib36","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1172\/JCI70895","article-title":"Topical hypochlorite ameliorates NF-kappaB-mediated skin diseases in mice","volume":"123","author":"Leung","year":"2013","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jaad.2017.12.024_bib37","unstructured":"Baeumer W. Anti-itch properties of a 0.05 % hypochlorous acid gel in a chronic mouse model of atopic dermatitis\u2014implications for direct effect on neurons. Poster presented at: the Dermatology Innovation Forum; March 13, 2013; Orlando, FL."},{"key":"10.1016\/j.jaad.2017.12.024_bib38","unstructured":"Draelos Z, Cash K. Evaluation of a gel formulation of hypochlorous acid and sodium hypochlorite to reduce pruritus in mild to moderate atopic dermatitis. Poster presented at: the Winter Clinical Dermatology Meeting; January 14, 2012; Maui, HI."},{"issue":"5","key":"10.1016\/j.jaad.2017.12.024_bib39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1600-0625.2009.00844.x","article-title":"Opioids and the skin\u2014where do we stand?","volume":"18","author":"Bigliardi","year":"2009","journal-title":"Exper Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.12.024_bib40","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","article-title":"Antipruritic treatment with systemic mu-opioid receptor antagonists: a review","volume":"63","author":"Phan","year":"2010","journal-title":"J Amer Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.12.024_bib41","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"10.1016\/j.jaad.2017.12.024_bib42","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","article-title":"Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstrom","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.108.143925","article-title":"Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates","volume":"328","author":"Ko","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"10.1016\/j.jaad.2017.12.024_bib44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1021\/jm00067a004","article-title":"A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines","volume":"36","author":"Naylor","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaad.2017.12.024_bib46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-3-662-44605-8_16","article-title":"Targeting itch with ligands selective for kappa opioid receptors","volume":"226","author":"Cowan","year":"2015","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2011.10217.x","article-title":"Targeted treatment of pruritus: a look into the future","volume":"165","author":"Tey","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.12.024_bib48","unstructured":"Bishop K, Visonneau S, McGuire D. Development of asimadoline, a selective kappa opioid receptor agonist, for the treatment of pruritus. Presented at: 8th World Congress on Itch (WCI); September 27, 2015; Nara, Japan."},{"key":"10.1016\/j.jaad.2017.12.024_bib49","unstructured":"Cowan A, Inan S. Kappa opioid agonists as potential antipruritics. Presented at: 40th annual meeting for the Society for Neuroscience; November 13, 2010; San Diego, CA."},{"issue":"4","key":"10.1016\/j.jaad.2017.12.024_bib51","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1476-5381.1994.tb17142.x","article-title":"A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753","volume":"113","author":"Barber","year":"1994","journal-title":"Br J Pharmacol"},{"issue":"5 Suppl","key":"10.1016\/j.jaad.2017.12.024_bib52","doi-asserted-by":"crossref","first-page":"732S","DOI":"10.1093\/ajcn\/57.5.732S","article-title":"Fatty acid metabolism in health and disease: the role of delta-6-desaturase","volume":"57","author":"Horrobin","year":"1993","journal-title":"Am J Clin Nutr"},{"issue":"1 Suppl","key":"10.1016\/j.jaad.2017.12.024_bib53","doi-asserted-by":"crossref","first-page":"367s","DOI":"10.1093\/ajcn\/71.1.367S","article-title":"Essential fatty acid metabolism and its modification in atopic eczema","volume":"71","author":"Horrobin","year":"2000","journal-title":"Am J Clin Nutr"},{"issue":"S1","key":"10.1016\/j.jaad.2017.12.024_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1399-3038.1991.tb00317.x","article-title":"Essential fatty acids and atopic dermatitis","volume":"2","author":"Wright","year":"1991","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2017.12.024_bib55","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0262-1746(82)90019-1","article-title":"Reduced levels of prostaglandin precursors in the blood of atopic patients: defective delta-6-desaturase function as a biochemical basis for atopy","volume":"9","author":"Manku","year":"1982","journal-title":"Prostaglandins Leukot Med"},{"issue":"2","key":"10.1016\/j.jaad.2017.12.024_bib56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12325-014-0093-0","article-title":"Gamma-linolenic acid levels correlate with clinical efficacy of evening primrose oil in patients with atopic dermatitis","volume":"31","author":"Simon","year":"2014","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdermsci.2015.03.010","article-title":"Dihomo-gamma-linolenic acid prevents the development of atopic dermatitis through prostaglandin D1 production in NC\/Tnd mice","volume":"79","author":"Amagai","year":"2015","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11745-007-3129-2","article-title":"Oral administration of dihomo-gamma-linolenic acid prevents development of atopic dermatitis in NC\/Nga mice","volume":"43","author":"Kawashima","year":"2008","journal-title":"Lipids"},{"key":"10.1016\/j.jaad.2017.12.024_bib59","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.jaad.2017.12.024_bib60","unstructured":"Thaci D. DS107 clinical data: A novel treatment for moderate to severe atopic dermatitis in adults. Abstract FC03.01. Presented at: the European Academy of Dermatology and Venereology Annual Meeting 2016 (EADV 2016); September 28-October 2, 2016; Vienna, Austria."},{"issue":"13-14","key":"10.1016\/j.jaad.2017.12.024_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00508-005-0394-z","article-title":"Plasma levels of polyunsaturated fatty acids in children with atopic dermatitis and in atopic and nonatopic controls","volume":"117","author":"Focke","year":"2005","journal-title":"Wiener Klin Wochenschr"},{"key":"10.1016\/j.jaad.2017.12.024_bib62","author":"Clinicaltrials.gov"},{"issue":"8","key":"10.1016\/j.jaad.2017.12.024_bib63","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/sj.jid.5700818","article-title":"The pruritus receptor unit: a target for novel therapies","volume":"127","author":"Yosipovitch","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"47","key":"10.1016\/j.jaad.2017.12.024_bib64","doi-asserted-by":"crossref","first-page":"36781","DOI":"10.1074\/jbc.M006480200","article-title":"Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes","volume":"275","author":"Oda","year":"2000","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.jaad.2017.12.024_bib65","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2222.2004.01876.x","article-title":"Pruritus-associated response mediated by cutaneous histamine H3 receptors","volume":"34","author":"Sugimoto","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2465","article-title":"The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines","volume":"7","author":"Thurmond","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.jaad.2017.12.024_bib67","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaci.2008.12.1110","article-title":"The histamine H4 receptor is functionally expressed on T(H)2 cells","volume":"123","author":"Gutzmer","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2017.12.024_bib68","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.jid.5701250","article-title":"Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor","volume":"128","author":"Dijkstra","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.12.024_bib69","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/sj.bjp.0705754","article-title":"Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice","volume":"142","author":"Bell","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaci.2006.08.034","article-title":"Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus","volume":"119","author":"Dunford","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0625.2008.00762.x","article-title":"Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation","volume":"18","author":"Rossbach","year":"2009","journal-title":"Exper Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.12.024_bib72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.12.024_bib73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2131\/jts.34.427","article-title":"Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist","volume":"34","author":"Yamaura","year":"2009","journal-title":"J Toxicol Sci"},{"issue":"2-3","key":"10.1016\/j.jaad.2017.12.024_bib74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0014-2999(01)01588-6","article-title":"Antipruritic activity of the kappa-opioid receptor agonist, TRK-820","volume":"435","author":"Togashi","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaad.2017.12.024_bib75","first-page":"95","article-title":"A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389), a potent, oral histamine H-4 receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults [abstract]","volume":"71","author":"Werfel","year":"2016","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jaad.2017.12.024_bib76","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/jdv.12753","article-title":"Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1\/Th2\/Th17 cytokines in adults with atopic dermatitis","volume":"29","author":"Batista","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2017.12.024_bib77","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.12.024_bib78","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1067\/mai.2003.1414","article-title":"Polarized in\u00a0vivo expression of IL-11 and IL-17 between acute and chronic skin lesions","volume":"111","author":"Toda","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2017.12.024_bib79","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/jid.2014.141","article-title":"A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis","volume":"134","author":"Dhingra","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.12.024_bib80","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2017.12.024_bib81","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2017.12.024_bib82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1684\/ecn.2013.0333","article-title":"Cytokines and T cells in atopic dermatitis","volume":"24","author":"Auriemma","year":"2013","journal-title":"Eur Cytokine Netw"},{"issue":"5","key":"10.1016\/j.jaad.2017.12.024_bib84","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.jid.2017.02.329","article-title":"A pathogenic role for Th22\/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22\/ILV-094 mAb","volume":"137","author":"Guttman-Yassky","year":"2017","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217328268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217328268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:45:05Z","timestamp":1759272305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217328268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0190962217328268"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.12.024","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapies for atopic dermatitis: Additional treatment classes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(18)30135-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}